700468Oval Medical Advanced Epinephrine Autoinjector Proof of MarketClosedGRD Proof of MarketInnovate UKOval's advanced Epinephrine Autoinjector is intended to address some of the fundamental causes of fatalities due to severe anaphylactic shock (allergic reaction), particularly in the high risk group of teenagers and young adults. This group is particularly at risk due to: - Rising incidence of allergy in younger generations - Poor compliance and attitude to risk of this age group - Difficulty in using some existing Epinephrine Autoinjectors without previous experience or regular training - Fear of self-injection Based on extensive experience of human factors in this market, Oval has generated a novel approach to address many of these issues. This project will allow us to test this approach and understand the likely effectiveness and acceptability of a new device